International law firm McDermott Will & Schulte represented ADAR1 Capital Management, LLC (ADAR1 Capital) in its campaign at Keros Therapeutics, Inc. (Keros), which resulted in a significant return of capital to Keros shareholders. On October 15, 2025, Keros announced its agreement to repurchase ADAR1 Capital’s entire stake, the launch of a public tender offer, and a commitment to distribute 25% of any net cash proceeds it receives from its global licensing agreement with Takeda Pharmaceuticals U.S.A., Inc. before December 31, 2028, to Keros stockholders. The announcement followed ADAR1 Capital’s “withhold” campaign at Keros’ 2025 Annual Meeting of Stockholders.

The McDermott team was led by Ele Klein, Brandon Gold, and Adriana Schwartz, and included Daniel Goldstein and Samuel Dayan.

Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.